Interferon-based treatment of hepatitis C virus infection reduces all-cause mortality in patients with end-stage renal disease an 8-year nationwide cohort study in Taiwan

Medicine (United States)

Volumn 94, Issue 47, 2015, Pages e2113-

  Hsu, Yueh Han ^a,b   Hung, Peir Haur ^c   Muo, Chih Hsin ^d,e,f   Tsai, Wen Chen ^a   Hsu, Chih Cheng ^a   Kao, Chia Hung ^d,g  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b Min Hwei College of Health Care Management   (Taiwan)

^c CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY   (Taiwan)

^f NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; ANTIVIRUS AGENT;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; IMMUNOTHERAPY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MORTALITY RISK; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEPSIS; SURVIVAL RATE; AGE; COMORBIDITY; DEMOGRAPHY; KAPLAN MEIER METHOD; KIDNEY FAILURE, CHRONIC; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; TAIWAN;

ADULT; AGE FACTORS; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; COMORBIDITY; FEMALE; HEPATITIS C; HUMANS; INTERFERONS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RESIDENCE CHARACTERISTICS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; TAIWAN;

EID: 84983527700     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002113     Document Type: Review

References (30)

1. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007;18:1584-1593.
2. Yu YC, Wang Y, He CL, et al. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol. 2014;6:419-425.
3. Fabrizi F, Messa P, Martin P. Health-related quality of life in dialysis patients with HCV infection. Int J Artif Organs. 2009;32:473-481.
4. Tsai HB, Chen PC, Liu CH, et al. Association of hepatitis C virus infection and malnutrition-inflammation complex syndrome in maintenance hemodialysis patients. Nephrol Dial Transplant. 2012;27:1176-1183.
5. Fabrizi F, Messa P, Martin P. Recent advances on hepatitis C virus in dialysis population. Kidney Blood Press Res. 2014;39:260-271.
6. United States Renal Data System. Annual Data Report: Epidemiology of Kidney Disease in the United States. 2014. Accessed 31May, 2015. In press.
7. Hsu YH, Muo CH, Liu CY, et al. Hepatitis C virus infection increases the risk of developing peripheral arterial disease: a 9-year population-based cohort study. J Hepatol. 2015;62:519-525.
8. Petta S, Macaluso FS, Craxi A. Cardiovascular diseases and HCV infection: a simple association or more? Gut. 2014;63:369-375.
9. Hsu CS, Huang CJ, Kao JH, et al. Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS One. 2013;8:e70458.
10. Hsu YC, Ho HJ, Huang YT, et al. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64:495-503.
11. Hsu CS, Kao JH, Chao YC, et al. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther. 2013;38: 415-423.
12. Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302.
13. Goodkin DA, Bieber B, Gillespie B, et al. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol. 2013;38:405-412.
14. National Health Insurance Administration MoHaW. 2014-2015 National Health Insurance Annual Report. 2014:122. http://www.nhi.gov.tw/Resource/webdata/13767-1-NHI2014-2015%20 Annual%20 Report%20 (bilingual)-141230.pdf. Accessed 29 April, 2015.
15. Administration TNHI. Regulations Governing the Exemption of the National Health Insurance Beneficiaries from the Co-Payment. 2011; http://www.nhi.gov.tw/English/webdata/webdata.aspx?menu=11&menu-id=295&WD-ID=295&webdata-id-=295&webdata-id=2431. Accessed March 15, 2015.
16. Liu CY, Chuang HY, Chen YL, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manage. 2006;4:1-22.
17. Kojima A, Kakizaki S, Hosonuma K, et al. Interferon treatment for patients with chronic hepatitis C complicated with chronic renal failure receiving hemodialysis. J Gastroenterol Hepatol. 2013;28:690-699.
18. Bose B, McDonald SP, Hawley CM, et al. Effect of dialysis modality on survival of hepatitis C-infected ESRF patients. Clin J Am Soc Nephrol. 2011;6:2657-2661.
19. Olubamwo OO, Onyeka IN, Miettola J, et al. Hepatitis C as a risk factor for carotid atherosclerosis: a systematic review. Clin Physiol Funct Imaging. 2015;26:12229.
20. Lee MH, Yang HI, Wang CH, et al. Hepatitis C virus infection and increased risk of cerebrovascular disease. Stroke. 2010;41:2894-2900.
21. White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49:831-844.
22. Chen YC, Lin HY, Li CY, et al. A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney Int. 2014;85:1200-1207.
23. Younossi ZM, Stepanova M, Nader F, et al. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647-652.
24. Su FH, Su CT, Chang SN, et al. Association of hepatitis C virus infection with risk of ESRD: a population-based study. Am J Kidney Dis. 2012;60:553-560.
25. Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013;84:874-879.
26. Liu CH, Kao JH. Treatment of hepatitis C virus infection in patients with end-stage renal disease. J Gastroenterol Hepatol. 2011;26: 228-239.
27. Liu CJ, Chu YT, Shau WY, et al. Treatment of patients with dual hepatitis C and B by peginterferon alpha and ribavirin reduced risk of hepatocellular carcinoma and mortality. Gut. 2014;63:506-514.
28. Gordon CE, Uhlig K, Lau J, et al. Interferon treatment in hemodialysis patients with chronic hepatitis C virus infection: a systematic review of the literature and meta-analysis of treatment efficacy and harms. Am J Kidney Dis. 2008;51:263-277.
29. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2008:S1-S99.
30. Butt AA, Evans R, Skanderson M, et al. Comorbid medical and psychiatric conditions and substance abuse in HCV infected persons on dialysis. J Hepatol. 2006;44:864-868.